药物洗脱微球与传统经导管动脉化疗栓塞治疗肝细胞癌的成本效果分析表2

数据集获取（Figshare）

• 源站标题：Table_2_Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma.xlsx
• DOI：10.3389/fpubh.2022.963058.s002
• 发布日期：2022-10-26
• 文件数：1 个
• 文件总体积：10.77 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_2_Cost-effectiveness_analysis_of_drug-eluting_beads_and_conventional_transarterial_chemoembolization_in_the_treatment_of_hepatocellular_carcinoma_xlsx/21398595

命令行下载

curl -L -o "Table_2_Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinom.xlsx" "https://ndownloader.figshare.com/files/37990482"

文件清单

• Table_2_Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinom.xlsx（10.77 KB）

文件总体积 10.77 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

ObjectiveTo conduct a cost-effectiveness analysis of drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) and conventional transcatheter arterial chemoembolization (cTACE) for first-line treatment of hepatocellular carcinoma (HCC) from the perspective of the Chinese healthcare system.
MethodsBased on the real-world clinical data of HCC patients receiving interventional therapy, a partitioned survival model was constructed for cost-effectiveness analysis. The model period is 1 month, and the research time limit is 10 years. The incremental cost-effectiveness ratio (ICER) is used as the evaluation index. One-way sensitivity analysis and probabilistic sensitivity analysis were used to analyze the uncertainty of parameters to test the stability of the model results.
ResultsThe ICER of the DEB-TACE group was 11,875.62 $/QALYs, which was lower than the willingness to pay threshold (WTP) of 31,499.23 $/QALYs. One-way sensitivity analysis suggested that the utility value of progression-free survival (PFS) in the DEB-TACE group had the greatest impact. Probabilistic sensitivity analysis showed that at the level of WTP of 31,499.23 $/QALYs, DEB-TACE had a cost-effective probability of 92%.
ConclusionUnder the current economic level in my country, DEB-TACE is more cost-effective than cTACE in the treatment of HCC patients.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fpubh.2022.963058.s002（source: https://frontiersin.figshare.com/articles/dataset/Table_2_Cost-effectiveness_analysis_of_drug-eluting_beads_and_conventional_transarterial_chemoembolization_in_the_treatment_of_hepatocellular_carcinoma_xlsx/21398595）。